Te‐Chun Hsia

7.2k total citations · 1 hit paper
155 papers, 2.1k citations indexed

About

Te‐Chun Hsia is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Te‐Chun Hsia has authored 155 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pulmonary and Respiratory Medicine, 53 papers in Molecular Biology and 51 papers in Oncology. Recurrent topics in Te‐Chun Hsia's work include Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Colorectal Cancer Treatments and Studies (14 papers). Te‐Chun Hsia is often cited by papers focused on Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Colorectal Cancer Treatments and Studies (14 papers). Te‐Chun Hsia collaborates with scholars based in Taiwan, United States and China. Te‐Chun Hsia's co-authors include Jing‐Gung Chung, Chih‐Yen Tu, Te‐Chun Shen, DA-TIAN BAU, Chia‐Hung Chen, Jai‐Sing Yang, Wu‐Huei Hsu, Chia-Wen Tsai, Michael Blankenburg and Thomas Prindiville and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Te‐Chun Hsia

146 papers receiving 2.0k citations

Hit Papers

Pembrolizumab Plus Ipilim... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
    2021 165 citations Michael Boyer, Mehmet Alı Nahıt Şendur et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Te‐Chun Hsia 809 581 551 293 168 155 2.1k
Yun Li 1.1k 1.4× 594 1.0× 336 0.6× 419 1.4× 191 1.1× 96 2.2k
Jen‐Yu Hung 1.1k 1.3× 358 0.6× 558 1.0× 356 1.2× 124 0.7× 77 2.2k
Jenny T. Mao 572 0.7× 443 0.8× 369 0.7× 267 0.9× 128 0.8× 44 1.7k
Faguang Jin 1.1k 1.3× 860 1.5× 398 0.7× 270 0.9× 274 1.6× 143 2.8k
Jing Lü 1.3k 1.6× 374 0.6× 556 1.0× 525 1.8× 224 1.3× 152 2.6k
Simon D. Spivack 1.4k 1.7× 655 1.1× 537 1.0× 786 2.7× 127 0.8× 62 2.8k
Jian Shen 940 1.2× 222 0.4× 336 0.6× 433 1.5× 283 1.7× 110 2.1k
Kiyoko Oshima 586 0.7× 305 0.5× 500 0.9× 140 0.5× 454 2.7× 87 1.7k
Soon‐Chan Hong 778 1.0× 589 1.0× 713 1.3× 298 1.0× 716 4.3× 116 2.3k

Countries citing papers authored by Te‐Chun Hsia

Since Specialization
Citations

This map shows the geographic impact of Te‐Chun Hsia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Te‐Chun Hsia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Te‐Chun Hsia more than expected).

Fields of papers citing papers by Te‐Chun Hsia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Te‐Chun Hsia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Te‐Chun Hsia. The network helps show where Te‐Chun Hsia may publish in the future.

Co-authorship network of co-authors of Te‐Chun Hsia

This figure shows the co-authorship network connecting the top 25 collaborators of Te‐Chun Hsia. A scholar is included among the top collaborators of Te‐Chun Hsia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Te‐Chun Hsia. Te‐Chun Hsia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Chia‐Hung, et al.. (2024). Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs. BMC Pulmonary Medicine. 24(1). 517–517. 3 indexed citations
3.
Liu, De-Yi, et al.. (2024). Effects of Hyperbaric Oxygen Therapy on Long COVID: A Systematic Review. Life. 14(4). 438–438. 4 indexed citations
4.
5.
6.
Lin, Ying‐Chun, et al.. (2023). Health Economic Evaluation of Proton Therapy for Lung Cancer: A Systematic Review. International Journal of Environmental Research and Public Health. 20(6). 4727–4727. 1 indexed citations
7.
Liam, Chong Kin, Te‐Chun Hsia, Jianying Zhou, et al.. (2023). Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR -Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical Cancer Research. 29(10). 1879–1886. 22 indexed citations
8.
Huang, Yi‐Ping, Te‐Chun Hsia, Yi‐Shih Ma, et al.. (2023). PW06 Triggered Fas-FADD to Induce Apoptotic Cell Death In Human Pancreatic Carcinoma MIA PaCa-2 Cells through the Activation of the Caspase-Mediated Pathway. Oxidative Medicine and Cellular Longevity. 2023. 1–11. 3 indexed citations
9.
Chiu, Kuo-Liang, et al.. (2023). Novel genetic variants in long non-coding RNA MEG3 are associated with the risk of asthma. PeerJ. 11. e14760–e14760. 7 indexed citations
10.
Tsai, Chia-Wen, et al.. (2023). Non-Homologous End-Joining Pathway Genotypes Significantly Associated with Nasopharyngeal Carcinoma Susceptibility. Biomedicines. 11(6). 1648–1648. 7 indexed citations
11.
Chen, Chia‐Hung, Chih‐Yen Tu, Wei‐Chih Liao, et al.. (2021). P12‐5: Correlation between bispectral index (BIS) and modified observer's assessment of alertness/sedation (MOAA/S) score in flexible bronchoscopy. Respirology. 26(S3). 416–416.
12.
Boyer, Michael, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, et al.. (2021). Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology. 39(21). 2327–2338. 165 indexed citations breakdown →
13.
Liao, Wei‐Chih, Wei‐Chun Chen, Te‐Chun Hsia, et al.. (2020). When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment. International Journal of COPD. Volume 15. 3375–3384. 4 indexed citations
14.
Yang, James Chih‐Hsin, Karen L. Reckamp, Young‐Chul Kim, et al.. (2020). Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports. 2(2). 100114–100114. 19 indexed citations
15.
Shen, Te‐Chun, WEN-SHIN CHANG, Te‐Chun Hsia, et al.. (2019). <p>Contribution of programmed cell death 6 genetic variations, gender, and smoking status to lung cancer</p>. OncoTargets and Therapy. Volume 12. 6237–6244. 8 indexed citations
16.
Shen, Te‐Chun, Chia‐Hung Chen, Cheng‐Li Lin, et al.. (2018). Risk of pleural empyema in patients with schizophrenia: a nationwide propensity-matched cohort study in Taiwan. BMJ Open. 8(7). e021187–e021187. 7 indexed citations
17.
Shen, Te‐Chun, Pei‐Ying Chang, Cheng‐Li Lin, et al.. (2016). Periodontal Treatment Reduces Risk of Adverse Respiratory Events in Patients With Chronic Obstructive Pulmonary Disease. Medicine. 95(20). e3735–e3735. 32 indexed citations
18.
Shen, Te‐Chun, I‐Kuan Wang, Chang‐Ching Wei, et al.. (2015). The Risk of Septicemia in End-Stage Renal Disease With and Without Renal Transplantation. Medicine. 94(34). e1437–e1437. 10 indexed citations
19.
Shen, Te‐Chun, Wei Chen, Cheng‐Li Lin, et al.. (2014). Chronic Obstructive Pulmonary Disease is Associated with an Increased Risk of Peripheral Arterial Disease. 25(4). 272–280. 1 indexed citations
20.
Ji, Bin‐Chuan, CHIEN-CHIH YU, Te‐Chun Hsia, et al.. (2012). Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells. Oncology Reports. 27(4). 959–964. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yun Li Breakdown of academic impact, for papers by Jen‐Yu Hung Breakdown of academic impact, for papers by Jenny T. Mao Breakdown of academic impact, for papers by Faguang Jin Breakdown of academic impact, for papers by Jing Lü Breakdown of academic impact, for papers by Simon D. Spivack Breakdown of academic impact, for papers by Jian Shen Breakdown of academic impact, for papers by Kiyoko Oshima Breakdown of academic impact, for papers by Soon‐Chan Hong
Rankless by CCL
2026